Drug Profile
Research programme: cell adhesion antagonists - ICOS
Alternative Names: Cell adhesion molecule antagonists research programme - ICOSLatest Information Update: 24 Mar 2009
Price :
$50
*
At a glance
- Originator ICOS Corporation
- Class Small molecules
- Mechanism of Action Cell adhesion molecule inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Fibrosis; Inflammation; Psoriasis
Most Recent Events
- 29 Jan 2007 ICOS Corporation has been acquired by Eli Lilly and Company
- 10 Jul 2006 This programme is still in active development
- 11 Dec 2003 Preclinical development for Fibrosis in USA (unspecified route)